Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.

Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Cancer Res. 2018 Sep 15;24(18):4579-4587. doi: 10.1158/1078-0432.CCR-18-0267. Epub 2018 Jun 13.

PMID:
29898990
2.

Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.

Romero OA, Verdura S, Torres-Diz M, Gomez A, Moran S, Condom E, Esteller M, Villanueva A, Sanchez-Cespedes M.

Oncogene. 2017 Mar 2;36(9):1287-1296. doi: 10.1038/onc.2016.296. Epub 2016 Sep 5.

PMID:
27593925
3.

BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.

Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF.

Oncogene. 2016 Sep 29;35(39):5179-90. doi: 10.1038/onc.2016.50. Epub 2016 Mar 21.

PMID:
26996667
4.

Expression inactivation of SMARCA4 by microRNAs in lung tumors.

Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L, Carretero J, Farez-Vidal E, Cuadros M, Reyes-Zurita FJ, Lupiáñez JA, Sánchez-Cespedes M, Slack FJ, Medina PP.

Hum Mol Genet. 2015 Mar 1;24(5):1400-9. doi: 10.1093/hmg/ddu554. Epub 2014 Oct 29.

5.

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.

Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A.

Cancer Res. 2014 Nov 1;74(21):5978-88. doi: 10.1158/0008-5472.CAN-14-1606. Epub 2014 Sep 12.

6.

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.

Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.

7.

The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases.

Romero OA, Sanchez-Cespedes M.

Oncogene. 2014 May 22;33(21):2681-9. doi: 10.1038/onc.2013.227. Epub 2013 Jun 10. Review.

PMID:
23752187
8.

The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer.

Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, Pisano D, Condom E, Villanueva A, Hager GL, Sanchez-Cespedes M.

EMBO Mol Med. 2012 Jul;4(7):603-16. doi: 10.1002/emmm.201200236. Epub 2012 Apr 11.

9.

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M.

Hum Mutat. 2008 May;29(5):617-22. doi: 10.1002/humu.20730.

PMID:
18386774
10.

Preliminary observations on application of ethibloc in necrohemorrhagic acute pancreatitis in humans.

Torino FD, Portillo NA, Romero OA, Garaycoechea ME, Deluca E, Perera SG.

Mt Sinai J Med. 1985 May;52(5):343-6. No abstract available.

PMID:
3874353

Supplemental Content

Loading ...
Support Center